Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
- Written by PR Newswire
 |
- ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers.
- ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat.
- ORSERDU is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations, a major unmet need.
FLORENCE,...
